Cargando…
Apolipoprotein C-III in patients with systemic lupus erythematosus
BACKGROUND: Systemic lupus erythematosus (SLE) has been associated with atherosclerotic cardiovascular disease (CV) and an altered lipid profile. High levels of apolipoprotein C-III (ApoC3) are associated with elevated triglyceride levels and an increased risk of CV. In the present study, we aimed t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088095/ https://www.ncbi.nlm.nih.gov/pubmed/35538496 http://dx.doi.org/10.1186/s13075-022-02793-y |
_version_ | 1784704296075395072 |
---|---|
author | Martín-González, Candelaria Ferrer-Moure, Carmen Carlos Quevedo-Abeledo, Juan de Vera-González, Antonia González-Delgado, Alejandra Sánchez-Martín, Julio González-Gay, Miguel Á. Ferraz-Amaro, Iván |
author_facet | Martín-González, Candelaria Ferrer-Moure, Carmen Carlos Quevedo-Abeledo, Juan de Vera-González, Antonia González-Delgado, Alejandra Sánchez-Martín, Julio González-Gay, Miguel Á. Ferraz-Amaro, Iván |
author_sort | Martín-González, Candelaria |
collection | PubMed |
description | BACKGROUND: Systemic lupus erythematosus (SLE) has been associated with atherosclerotic cardiovascular disease (CV) and an altered lipid profile. High levels of apolipoprotein C-III (ApoC3) are associated with elevated triglyceride levels and an increased risk of CV. In the present study, we aimed to study circulating ApoC3 in patients with SLE and describe its relationship with the manifestations of the disease. METHODS: This is a cross-sectional study that included 186 patients with SLE. Disease-related data, CV comorbidity, full lipid profile, and serum levels of ApoC3 were assessed. A multivariable regression analysis was performed to study how ApoC3 was related to SLE features. RESULTS: Classic CV risk factors were significantly and strongly associated with circulating ApoC3. After a fully multivariable analysis that included classic CV risk factors and lipid profile molecules, SLICC damage (beta coef. 0.10 [95% CI 0.02–0.19] mg/dl, 0.020) and Katz severity (beta coef. 0.11 [95% CI 0.03–0.19] mg/dl, p = 0.011) indices and SLEDAI activity score (beta coef. 0.05 [95% CI 0.05–0.08] mg/dl, p = 0.004) were all independently associated with higher levels of circulating ApoC3. CONCLUSION: Among SLE patients, disease activity, severity, and disease damage are independently associated with higher ApoC3 serum levels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-022-02793-y. |
format | Online Article Text |
id | pubmed-9088095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90880952022-05-11 Apolipoprotein C-III in patients with systemic lupus erythematosus Martín-González, Candelaria Ferrer-Moure, Carmen Carlos Quevedo-Abeledo, Juan de Vera-González, Antonia González-Delgado, Alejandra Sánchez-Martín, Julio González-Gay, Miguel Á. Ferraz-Amaro, Iván Arthritis Res Ther Research Article BACKGROUND: Systemic lupus erythematosus (SLE) has been associated with atherosclerotic cardiovascular disease (CV) and an altered lipid profile. High levels of apolipoprotein C-III (ApoC3) are associated with elevated triglyceride levels and an increased risk of CV. In the present study, we aimed to study circulating ApoC3 in patients with SLE and describe its relationship with the manifestations of the disease. METHODS: This is a cross-sectional study that included 186 patients with SLE. Disease-related data, CV comorbidity, full lipid profile, and serum levels of ApoC3 were assessed. A multivariable regression analysis was performed to study how ApoC3 was related to SLE features. RESULTS: Classic CV risk factors were significantly and strongly associated with circulating ApoC3. After a fully multivariable analysis that included classic CV risk factors and lipid profile molecules, SLICC damage (beta coef. 0.10 [95% CI 0.02–0.19] mg/dl, 0.020) and Katz severity (beta coef. 0.11 [95% CI 0.03–0.19] mg/dl, p = 0.011) indices and SLEDAI activity score (beta coef. 0.05 [95% CI 0.05–0.08] mg/dl, p = 0.004) were all independently associated with higher levels of circulating ApoC3. CONCLUSION: Among SLE patients, disease activity, severity, and disease damage are independently associated with higher ApoC3 serum levels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-022-02793-y. BioMed Central 2022-05-10 2022 /pmc/articles/PMC9088095/ /pubmed/35538496 http://dx.doi.org/10.1186/s13075-022-02793-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Martín-González, Candelaria Ferrer-Moure, Carmen Carlos Quevedo-Abeledo, Juan de Vera-González, Antonia González-Delgado, Alejandra Sánchez-Martín, Julio González-Gay, Miguel Á. Ferraz-Amaro, Iván Apolipoprotein C-III in patients with systemic lupus erythematosus |
title | Apolipoprotein C-III in patients with systemic lupus erythematosus |
title_full | Apolipoprotein C-III in patients with systemic lupus erythematosus |
title_fullStr | Apolipoprotein C-III in patients with systemic lupus erythematosus |
title_full_unstemmed | Apolipoprotein C-III in patients with systemic lupus erythematosus |
title_short | Apolipoprotein C-III in patients with systemic lupus erythematosus |
title_sort | apolipoprotein c-iii in patients with systemic lupus erythematosus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088095/ https://www.ncbi.nlm.nih.gov/pubmed/35538496 http://dx.doi.org/10.1186/s13075-022-02793-y |
work_keys_str_mv | AT martingonzalezcandelaria apolipoproteinciiiinpatientswithsystemiclupuserythematosus AT ferrermourecarmen apolipoproteinciiiinpatientswithsystemiclupuserythematosus AT carlosquevedoabeledojuan apolipoproteinciiiinpatientswithsystemiclupuserythematosus AT deveragonzalezantonia apolipoproteinciiiinpatientswithsystemiclupuserythematosus AT gonzalezdelgadoalejandra apolipoproteinciiiinpatientswithsystemiclupuserythematosus AT sanchezmartinjulio apolipoproteinciiiinpatientswithsystemiclupuserythematosus AT gonzalezgaymiguela apolipoproteinciiiinpatientswithsystemiclupuserythematosus AT ferrazamaroivan apolipoproteinciiiinpatientswithsystemiclupuserythematosus |